CRO Selection for Small Pharma and Biotech -





Q3, 2011 

Some Contract Research Organizations (CROs) possess measurable differentiating characteristics that should play an important role in the selection process for clinical studies. This is especially important for small pharma and biotech sponsors that have needs that may be meaningfully different than large pharma. 

The challenge faced by the industry is that when making provider selections, development teams have only their own professional histories to reference. Unless a company, or the people it employs, has direct experience with a service provider, there is no independent assessment available to make a confident and informed purchase decision. 

ISR’s 2011 CRO Selection for Small Pharma and Biotech is designed to provide biopharmaceutical companies and service providers a view into how the consumers of these services grade their performance and how service providers are perceived by the broader market.